# A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

Study · id `cardio:ct-nct02453685` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02453685](<https://clinicaltrials.gov/study/NCT02453685>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02453685

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 335 participants.

## Technical summary

Registry record NCT02453685. Randomized; no masking; primary purpose treatment. Start 2015-08-31 (actual); primary completion 2016-09-20 (actual). Results posted on 2019-02-08.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 335 participants (enrolled count; ClinicalTrials.gov record NCT02453685, source copy `cardio:ctgov-nct02453685-2019-02-08`, retrieved 2026-10-26)
- Started: 2015-08-31 (actual) (ClinicalTrials.gov record NCT02453685, source copy `cardio:ctgov-nct02453685-2019-02-08`, retrieved 2026-10-26)
- Primary completion: 2016-09-20 (actual) (ClinicalTrials.gov record NCT02453685, source copy `cardio:ctgov-nct02453685-2019-02-08`, retrieved 2026-10-26)
- Completion: 2016-09-20 (actual) (ClinicalTrials.gov record NCT02453685, source copy `cardio:ctgov-nct02453685-2019-02-08`, retrieved 2026-10-26)
- Results first posted: 2019-02-08 (ClinicalTrials.gov record NCT02453685, source copy `cardio:ctgov-nct02453685-2019-02-08`, retrieved 2026-10-26)
- Countries: Australia; Bulgaria; Hungary; India; Serbia; South Korea; Thailand; Türkiye; United Arab Emirates (ClinicalTrials.gov record NCT02453685, source copy `cardio:ctgov-nct02453685-2019-02-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02453685-2019-02-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): biphasic insulin aspart 30
- Intervention (Drug): insulin glargine
- Intervention (Drug): insulin aspart
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 5e9d2a871f8b0c6ba9e5963f16478fabab74d460ca0de5a8b9cb61821222f470
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
